Which has preferable earnings and valuation, EVO or KRRO?

Evotec has higher revenue and earnings than Korro Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.80 -$117.12M N/A N/A Korro Bio $6.39M 25.93 -$117.26M -$11.67 N/A

Is EVO or KRRO more profitable?

Evotec has a net margin of -26.20% compared to Korro Bio's net margin of -1,834.48%. Evotec's return on equity of -24.93% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Korro Bio -1,834.48% -117.86% -71.04%

Is CLYM or KRRO more profitable?

Climb Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Climb Bio's return on equity of -31.45% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Korro Bio -1,834.48% -117.86% -71.04%

Which has stronger valuation & earnings, KRRO or OCS?

Korro Bio has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 25.93 -$117.26M -$11.67 N/A Oculis $1.45M 471.44 -$119.44M -$2.13 N/A

Is KRRO or OCS more profitable?

Korro Bio has a net margin of -1,834.48% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% Oculis -8,460.67% -56.78% -45.62%

Korro Bio (KRRO) Competitors

$11.44 -0.82 (-6.65%)

As of 03:52 PM Eastern

Compare

KRRO vs. EVO, ACRS, CLYM, SPRY, and OCS

Should you buy Korro Bio stock or one of its competitors? MarketBeat compares Korro Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Korro Bio include Evotec (EVO), Aclaris Therapeutics (ACRS), Climb Bio (CLYM), ARS Pharmaceuticals (SPRY), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

How does Korro Bio compare to Evotec?

Evotec (NASDAQ:EVO) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Evotec currently has a consensus price target of $3.00, indicating a potential upside of 49.25%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 45.47%. Given Evotec's higher possible upside, research analysts plainly believe Evotec is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Evotec has higher revenue and earnings than Korro Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.80	-$117.12M	N/A	N/A
Korro Bio	$6.39M	25.93	-$117.26M	-$11.67	N/A

Evotec has a net margin of -26.20% compared to Korro Bio's net margin of -1,834.48%. Evotec's return on equity of -24.93% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Korro Bio	-1,834.48%	-117.86%	-71.04%

5.8% of Evotec shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evotec had 27 more articles in the media than Korro Bio. MarketBeat recorded 27 mentions for Evotec and 0 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.00 beat Evotec's score of -0.26 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Evotec	Neutral
Korro Bio	Neutral

Evotec has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3, indicating that its stock price is 200% more volatile than the broader market.

Summary

Korro Bio beats Evotec on 8 of the 15 factors compared between the two stocks.

How does Korro Bio compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 0 mentions for Korro Bio. Aclaris Therapeutics' average media sentiment score of 1.04 beat Korro Bio's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Positive
Korro Bio	Neutral

Aclaris Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 102.61%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 45.47%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Aclaris Therapeutics has higher revenue and earnings than Korro Bio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	101.24	-$64.92M	-$0.56	N/A
Korro Bio	$6.39M	25.93	-$117.26M	-$11.67	N/A

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the broader market.

Aclaris Therapeutics has a net margin of -832.58% compared to Korro Bio's net margin of -1,834.48%. Aclaris Therapeutics' return on equity of -55.89% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Summary

Aclaris Therapeutics beats Korro Bio on 12 of the 15 factors compared between the two stocks.

How does Korro Bio compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Climb Bio has higher earnings, but lower revenue than Korro Bio. Climb Bio is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Korro Bio	$6.39M	25.93	-$117.26M	-$11.67	N/A

Climb Bio presently has a consensus price target of $21.73, suggesting a potential upside of 70.96%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 45.47%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Climb Bio is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Climb Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Climb Bio's return on equity of -31.45% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Climb Bio has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 2 more articles in the media than Korro Bio. MarketBeat recorded 2 mentions for Climb Bio and 0 mentions for Korro Bio. Climb Bio's average media sentiment score of 0.37 beat Korro Bio's score of 0.00 indicating that Climb Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Climb Bio	Neutral
Korro Bio	Neutral

Summary

Climb Bio beats Korro Bio on 11 of the 15 factors compared between the two stocks.

How does Korro Bio compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

ARS Pharmaceuticals has a net margin of -200.00% compared to Korro Bio's net margin of -1,834.48%. Korro Bio's return on equity of -117.86% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Korro Bio	-1,834.48%	-117.86%	-71.04%

In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Korro Bio. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 0 mentions for Korro Bio. ARS Pharmaceuticals' average media sentiment score of 0.59 beat Korro Bio's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ARS Pharmaceuticals	Positive
Korro Bio	Neutral

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ARS Pharmaceuticals presently has a consensus target price of $28.20, suggesting a potential upside of 323.42%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 45.47%. Given ARS Pharmaceuticals' higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

ARS Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, meaning that its stock price is 200% more volatile than the broader market.

Korro Bio has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	7.85	-$171.30M	-$2.01	N/A
Korro Bio	$6.39M	25.93	-$117.26M	-$11.67	N/A

Summary

ARS Pharmaceuticals beats Korro Bio on 9 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Oculis?

Korro Bio (NASDAQ:KRRO) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Korro Bio has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	25.93	-$117.26M	-$11.67	N/A
Oculis	$1.45M	471.44	-$119.44M	-$2.13	N/A

Korro Bio has a net margin of -1,834.48% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Oculis	-8,460.67%	-56.78%	-45.62%

Korro Bio currently has a consensus target price of $16.71, suggesting a potential upside of 45.47%. Oculis has a consensus target price of $38.33, suggesting a potential upside of 225.13%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oculis' average media sentiment score of 1.22 beat Korro Bio's score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company	Overall Sentiment
Korro Bio	Neutral
Oculis	Positive

Korro Bio has a beta of 3, indicating that its stock price is 200% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Summary

Korro Bio and Oculis tied by winning 8 of the 16 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$165.60M	$3.03B	$6.81B	$12.34B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-0.98	20.20	27.16	24.06
Price / Sales	25.93	782.31	573.91	113.10
Price / Cash	N/A	57.12	29.05	48.09
Price / Book	2.10	4.21	10.68	6.17
Net Income	-$117.26M	$65.46M	$3.59B	$331.63M
7 Day Performance	-14.89%	-2.61%	-1.50%	-1.48%
1 Month Performance	-11.55%	-0.82%	1.17%	-1.20%
1 Year Performance	-15.95%	17.37%	24.50%	17.62%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.0171 of 5 stars	$11.44 -6.7%	$16.71 +46.2%	-10.4%	$164.60M	$6.39M	N/A	70
EVO Evotec	3.5321 of 5 stars	$2.14 -11.9%	$7.00 +227.1%	-54.0%	$761.33M	$891.97M	N/A	4,553	Analyst Revision Gap Up High Trading Volume
ACRS Aclaris Therapeutics	3.0622 of 5 stars	$5.43 -1.3%	$11.50 +111.8%	+252.8%	$758.35M	$7.83M	N/A	100	News Coverage Positive News
CLYM Climb Bio	2.984 of 5 stars	$13.24 +0.2%	$21.73 +64.1%	+741.1%	$758.12M	N/A	N/A	9	Analyst Forecast
SPRY ARS Pharmaceuticals	3.2759 of 5 stars	$7.61 -1.7%	$28.20 +270.6%	-60.9%	$755.67M	$84.28M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors